Cargando…

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Detalles Bibliográficos
Autores principales:	Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paolo, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, Scambia, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616202/ https://www.ncbi.nlm.nih.gov/pubmed/37903774 http://dx.doi.org/10.1038/s41523-023-00596-1

Ejemplares similares

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
por: Fabi, Alessandra, et al.
Publicado: (2023)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
por: Lazzaro, Carlo, et al.
Publicado: (2013)

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
por: De Giglio, Andrea, et al.
Publicado: (2019)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer
por: Carbognin, Luisa, et al.
Publicado: (2022)

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
por: Sharmni Vishnu, K., et al.
Publicado: (2022)

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
por: Garufi, Giovanna, et al.
Publicado: (2022)

Impact of epilepsy and its treatment on brain metastasis from solid tumors: A retrospective study
por: Maschio, Marta, et al.
Publicado: (2022)

Tumor Lysis Syndrome After a Single Dose of Atezolizumab with Nab-Paclitaxel: A Case Report and Review of Literature
por: Carrier, Xavier, et al.
Publicado: (2020)

Atezolizumab in combination with carboplatin plus nab‐paclitaxel for managing combined large‐cell neuroendocrine carcinoma: A case report
por: Tsutsumi, Rei, et al.
Publicado: (2022)

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †
por: Orlandi, Armando, et al.
Publicado: (2020)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
por: Lombardi, Pasquale, et al.
Publicado: (2023)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
por: Chen, Yingkai, et al.
Publicado: (2022)

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
por: Duranti, Simona, et al.
Publicado: (2021)

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
por: Emens, L.A., et al.
Publicado: (2020)

Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting
por: Franco, Antonio, et al.
Publicado: (2023)

Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria
por: Deutschmann, Christine, et al.
Publicado: (2022)

Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer
por: Esposito, Angela, et al.
Publicado: (2015)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
por: Yamaguchi, Teppei, et al.
Publicado: (2019)

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
por: Roberto, Michela, et al.
Publicado: (2021)

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
por: Shiraishi, Yoshimasa, et al.
Publicado: (2022)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
por: Lammers, Philip, et al.
Publicado: (2014)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Toward precision medicine in inflammatory breast cancer
por: Viale, Giulia, et al.
Publicado: (2019)

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine
por: De Paolis, Elisa, et al.
Publicado: (2023)

Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients
por: Falcone, Rosa, et al.
Publicado: (2023)

Alpha-Lipoic Acid Downregulates IL-1β and IL-6 by DNA Hypermethylation in SK-N-BE Neuroblastoma Cells
por: Dinicola, Simona, et al.
Publicado: (2017)

BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
por: Pavese, Francesco, et al.
Publicado: (2022)

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
por: Gelao, Lucia, et al.
Publicado: (2014)

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
por: Marra, Antonio, et al.
Publicado: (2020)

Big Bang scientist nabbed
Publicado: (2009)

New Ways To Nab Nitrogen
por: Ritter, Stephen K.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5m7out81876ce6fd8jg2adcskv